tiprankstipranks
Trending News
More News >
Tivic Health Systems (TIVC)
NASDAQ:TIVC
US Market

Tivic Health Systems (TIVC) AI Stock Analysis

Compare
158 Followers

Top Page

TI

Tivic Health Systems

(NASDAQ:TIVC)

Rating:43Neutral
Price Target:
The overall stock score of 43 reflects Tivic Health Systems' current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock's technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.

Tivic Health Systems (TIVC) vs. SPDR S&P 500 ETF (SPY)

Tivic Health Systems Business Overview & Revenue Model

Company DescriptionTivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
How the Company Makes MoneyTivic Health Systems generates revenue primarily through the sale of its medical devices, particularly ClearUP Sinus Relief. The company sells its products directly to consumers through online platforms and retail partnerships. Additionally, Tivic may collaborate with healthcare providers and distributors to expand its market reach. The company's earnings are also influenced by its ongoing research and development efforts to introduce new products and innovations in the bioelectronic medicine field, potentially opening additional revenue streams in the future.

Tivic Health Systems Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q1-2025)
|
% Change Since: -14.12%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a period of significant strategic transformation for Tivic Health, with promising developments in their transition to a diversified immunotherapeutics company. The acquisition of Entolimod and advancements toward commercialization present considerable growth opportunities. However, the company faces financial challenges with declining revenue and cash reserves, balancing the positive strategic shifts.
Q1-2025 Updates
Positive Updates
Strategic Transition to Diversified Immunotherapeutics
Tivic Health has transitioned from a single product company to a diversified immunotherapeutics company, focusing on diseases related to immune system dysregulation.
Acquisition of Entolimod and Entolasta
Tivic Health secured exclusive worldwide rights to late-stage immunomodulatory drug candidate Entolimod and its derivative Entolasta, representing a significant value creation opportunity.
Increased Gross Margins
Gross margins increased from 50% to 72% due to reduced product support and fulfillment costs.
Strategic Financing and Capital Infusion
Tivic Health secured $8.4 million in tranche funding, a $25 million equity line of credit, and raised $1.7 million through an ATM program to support its strategic transformation.
FDA Fast Track and Orphan Drug Status
Entolimod received Fast Track and orphan drug status from the FDA for acute radiation syndrome (ARS), indicating potential for accelerated pathways and emergency use designations.
Negative Updates
Significant Revenue Decline
Revenue decreased to $70,000 from $334,000, primarily due to an 81% drop in unit sales resulting from a 92% reduction in advertising spend.
Decreased Cash Reserves
Cash and cash equivalents decreased to $669,000 from $2 million at the end of 2024, highlighting potential liquidity concerns despite recent capital raises.
Flat Net Loss
Net loss remained flat at $1.5 million for the first quarter of 2025, indicating ongoing financial challenges despite strategic shifts.
Company Guidance
In the first quarter of 2025, Tivic Health Systems reported a significant strategic transition, focusing on their evolution from a single-product company to a diversified immunotherapeutics entity. The company's revenue decreased to $70,000 from $334,000 the previous year, reflecting an 81% drop in unit sales due to a 92% reduction in advertising spend, as resources were redirected towards the Statera licensing agreement. Gross margins improved to 72% from 50%, and operating expenses remained steady at $1.6 million. Tivic reported a net loss of $1.5 million, consistent with the previous year, and had cash reserves of $669,000. They secured $8.4 million in strategic financing and a $25 million equity line of credit to support their transformation, particularly advancing the development of their newly acquired late-stage immunomodulatory drug candidate, Entolimod. Additionally, Tivic plans to enhance their vagus nerve stimulation program, with further updates expected in the coming months.

Tivic Health Systems Financial Statement Overview

Summary
Tivic Health Systems faces significant financial challenges with declining revenues, consistent losses, and negative cash flows. While the balance sheet shows a low debt level, reliance on external financing and a deteriorating asset base are concerns. Profitability and operational efficiency need improvement.
Income Statement
30
Negative
The income statement shows a concerning trajectory with declining revenues from $1,840,000 in 2022 to $780,000 in 2024 and consistent negative net income. Gross profit margins have deteriorated significantly, leading to negative EBIT and EBITDA margins. Despite these challenges, there was a slight improvement in the gross profit margin from negative to positive, but overall profitability remains weak.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with stockholders' equity exceeding total debt, resulting in a Debt-to-Equity Ratio of zero. However, total assets have been decreasing from $5,856,000 in 2022 to $2,807,000 in 2024, indicating asset deterioration. The equity ratio remains strong but declining equity and asset base are concerns.
Cash Flow
40
Negative
Cash flow analysis reveals negative operating cash flows, indicating operational challenges. Free cash flow remains negative, reflecting ongoing cash burn. Positive financing cash flows in recent years suggest reliance on external funding. The Free Cash Flow to Net Income Ratio is unfavorable, highlighting inefficiencies in cash generation.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
516.00K780.00K1.18M1.84M1.17M860.00K
Gross Profit
-115.00K2.00K287.00K299.00K-129.00K-225.00K
EBIT
-5.69M-5.66M-8.24M-10.10M-5.63M-3.20M
EBITDA
-5.73M-5.31M-8.06M-9.92M-6.65M-3.21M
Net Income Common Stockholders
-5.68M-5.66M-8.24M-10.10M-8.49M-4.08M
Balance SheetCash, Cash Equivalents and Short-Term Investments
669.00K2.00M3.40M3.52M12.97M1.04M
Total Assets
3.78M2.81M5.16M5.86M15.04M1.53M
Total Debt
0.000.00369.00K530.00K708.00K1.47M
Net Debt
-669.00K-2.00M-3.03M-2.99M-12.27M425.00K
Total Liabilities
741.00K272.00K1.58M2.23M1.76M2.71M
Stockholders Equity
3.04M2.54M3.58M3.63M13.27M-1.18M
Cash FlowFree Cash Flow
-4.95M-5.72M-8.63M-8.93M-5.61M-3.03M
Operating Cash Flow
-4.95M-5.72M-8.51M-8.92M-5.61M-3.03M
Investing Cash Flow
-526.00K0.00-118.00K-11.00K0.000.00
Financing Cash Flow
4.47M4.33M8.51M-528.00K17.54M1.76M

Tivic Health Systems Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.71
Price Trends
50DMA
4.45
Negative
100DMA
4.70
Negative
200DMA
4.75
Negative
Market Momentum
MACD
-0.16
Positive
RSI
38.95
Neutral
STOCH
19.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIVC, the sentiment is Negative. The current price of 3.71 is below the 20-day moving average (MA) of 4.08, below the 50-day MA of 4.45, and below the 200-day MA of 4.75, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 38.95 is Neutral, neither overbought nor oversold. The STOCH value of 19.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIVC.

Tivic Health Systems Risk Analysis

Tivic Health Systems disclosed 48 risk factors in its most recent earnings report. Tivic Health Systems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tivic Health Systems Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.27-45.10%3.30%16.81%0.02%
49
Neutral
$4.60M-136.26%9.57%10.03%
43
Neutral
$3.58M-218.77%-33.67%91.72%
38
Underperform
$268.78K-800.00%-35.03%59.34%
$2.60M-129.48%
IVIVF
39
Underperform
$2.83M-679.99%55.17%40.47%
29
Underperform
$2.48M-200.56%81.35%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TIVC
Tivic Health Systems
3.71
-3.25
-46.70%
HSDT
Helius Medical Technologies
0.51
-14.94
-96.70%
VTAK
Catheter Precision
0.36
-4.84
-93.08%
BBLG
Bone Biologics
4.77
-4.41
-48.04%
IVF
INVO Fertility
1.31
-11.53
-89.80%
BJDX
Bluejay Diagnostics
1.66
-160.66
-98.98%

Tivic Health Systems Corporate Events

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Tivic Health Regains Nasdaq Compliance
Positive
Apr 10, 2025

On April 10, 2025, Tivic Health Systems announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows a series of events where the company faced potential delisting due to its stock price falling below $1.00 for 33 consecutive days in 2024. After implementing a reverse stock split and meeting the necessary requirements, Nasdaq confirmed compliance, allowing Tivic Health to maintain its market position and providing stability for its stakeholders.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

Tivic Health Systems’ stock faces challenges primarily due to weak financial performance characterized by declining revenues and consistent losses. Despite strategic transformations and potential growth in pharmaceuticals, the current financial health and bearish technical indicators significantly impact the stock’s attractiveness. The company’s efforts to diversify and strategic acquisitions offer future potential but are currently overshadowed by the need for improved operational efficiency and profitability.

To see Spark’s full report on TIVC stock, click here.

Private Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
Tivic Health Systems Enters Equity Purchase Agreement
Positive
Mar 21, 2025

On March 18, 2025, Tivic Health Systems entered into an Equity Purchase Agreement with Mast Hill Fund, allowing Tivic to sell up to $25 million in common stock over 24 months. This agreement provides Tivic with financial flexibility to support its strategic initiatives, including expanding its biopharmaceutical program and advancing its non-invasive cervical vagus nerve stimulation devices. The company also reported a 30% reduction in net loss for 2024, reflecting improved financial management. Tivic’s recent strategic moves, including acquiring rights to Entolimod™ and appointing new leadership, aim to enhance its market position and drive growth in the biotech sector.

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Tivic Health Systems Announces Reverse Stock Split
Neutral
Mar 5, 2025

Tivic Health Systems, Inc. announced a 1-for-17 reverse stock split of its common stock, effective March 7, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. The reverse split is part of the company’s compliance plan to maintain its Nasdaq listing, following a notification from Nasdaq about non-compliance due to the stock’s low trading price. The reverse split will adjust the number of shares and conversion prices, but will not affect the overall ownership percentage of stockholders, aiming to increase the stock price above the $1.00 requirement.

Executive/Board ChangesBusiness Operations and Strategy
Tivic Health Systems Appoints New COO and President
Positive
Feb 24, 2025

On February 18, 2025, Tivic Health Systems announced the appointment of Michael Handley as Chief Operating Officer and President of its Tivic Biopharma division. Handley, a seasoned professional with extensive experience in drug and device commercialization, will lead Tivic’s efforts to advance its newly licensed product, Entolimod, through regulatory approval and commercialization. This strategic move aims to expand Tivic’s biopharmaceutical capabilities and enhance its therapeutics pipeline, potentially increasing shareholder value.

Product-Related AnnouncementsBusiness Operations and Strategy
Tivic Health Systems Secures Licensing Agreement with Statera
Positive
Feb 12, 2025

On February 11, 2025, Tivic Health Systems entered into an exclusive licensing agreement with Statera Biopharma to acquire rights to the TLR5 agonist program, including Entolimod for treating Acute Radiation Syndrome (ARS), and options for additional indications. This agreement positions Tivic as a diversified therapeutics company with a broadened clinical pipeline, potentially leading to FDA approval for ARS treatment within 24 months. Tivic’s acquisition aligns with its strategic transformation towards tackling immune and autonomic dysregulation. The deal involves milestone and royalty payments and allows Tivic to expand its product offerings, potentially benefiting shareholders by managing investments strategically.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.